Ritsuro Suzuki

Summary

Affiliation: Aichi Cancer Center
Country: Japan

Publications

  1. ncbi Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells
    R Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Nagoya, Japan
    Leukemia 18:763-70. 2004
  2. ncbi Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms
    R Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Kanokoden, Nagoya, Japan
    Bone Marrow Transplant 37:425-31. 2006
  3. ncbi Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0
    Ritsuro Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Nagoya, Japan
    Int J Hematol 77:482-9. 2003
  4. ncbi Comparison of genetic aberrations in CD10+ diffused large B-cell lymphoma and follicular lymphoma by comparative genomic hybridization and tissue-fluorescence in situ hybridization
    Xiaohua Zhang
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464-8681, Japan
    Cancer Sci 95:809-14. 2004
  5. ncbi Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type
    Yasuhiro Nakashima
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan
    Genes Chromosomes Cancer 44:247-55. 2005
  6. ncbi Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical sites
    Koichi Ichimura
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
    Pathol Int 53:333-44. 2003
  7. ncbi Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases
    Hiroyuki Tagawa
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, Aichi, Japan
    Cancer Res 64:5948-55. 2004
  8. ncbi Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM
    Hiroyuki Tagawa
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1-1-1 Kanokoden, Chikusa-ku, Aichi, Nagoya 464-8681, Japan
    Oncogene 24:1348-58. 2005
  9. ncbi Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients
    Takashi Oyama
    Department of Clinical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Clin Cancer Res 13:5124-32. 2007
  10. ncbi Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma
    Naoko Asano
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
    Int J Hematol 91:426-35. 2010

Detail Information

Publications56

  1. ncbi Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells
    R Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Nagoya, Japan
    Leukemia 18:763-70. 2004
    ..005). These findings suggest that ANKL is an entity of mature cytotoxic NK-cell neoplasms with distinct phenotype and disease presentations. Intensive treatment for ANKL may result in a better prognosis...
  2. ncbi Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms
    R Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Kanokoden, Nagoya, Japan
    Bone Marrow Transplant 37:425-31. 2006
    ..03). These findings suggest that the HSCT is a promising treatment strategy for NK-cell lineage...
  3. ncbi Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0
    Ritsuro Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Nagoya, Japan
    Int J Hematol 77:482-9. 2003
    ....
  4. ncbi Comparison of genetic aberrations in CD10+ diffused large B-cell lymphoma and follicular lymphoma by comparative genomic hybridization and tissue-fluorescence in situ hybridization
    Xiaohua Zhang
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464-8681, Japan
    Cancer Sci 95:809-14. 2004
    ..Taken together, our results indicate that CD10(+) DLBCL constitutes a unique subtype entity with genetic characteristics significantly different from those of FL and DLBCL...
  5. ncbi Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type
    Yasuhiro Nakashima
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan
    Genes Chromosomes Cancer 44:247-55. 2005
    ..3, 5q34-q35.3, 1p36.23-p36.33, 2p16.1-p16.3, 4q12, and 4q31.3-q32.1. Our results can be expected to provide further insights into the genetic basis of lymphomagenesis and the clinicopathologic features of NK-cell lymphomas/leukemias...
  6. ncbi Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical sites
    Koichi Ichimura
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
    Pathol Int 53:333-44. 2003
    ..This concept might provide a new insight enabling further understanding of the interrelationships among WHO T/NK-cell disease entities...
  7. ncbi Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases
    Hiroyuki Tagawa
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, Aichi, Japan
    Cancer Res 64:5948-55. 2004
    ..These results suggest that array-based comparative genomic hybridization analysis provides a platform of genomic aberrations of DLBCL both common and specific to clinically distinct subgroups...
  8. ncbi Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM
    Hiroyuki Tagawa
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1-1-1 Kanokoden, Chikusa-ku, Aichi, Nagoya 464-8681, Japan
    Oncogene 24:1348-58. 2005
    ..The high-resolution array CGH technology allowed for the precise identification of genomic aberrations and identification of BIM as a novel candidate tumor suppressor gene in MCL...
  9. ncbi Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients
    Takashi Oyama
    Department of Clinical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Clin Cancer Res 13:5124-32. 2007
    ..To further characterize this disease, age-related EBV+ B-cell LPDs were compared with EBV-negative diffuse large B-cell lymphomas (DLBCL)...
  10. ncbi Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma
    Naoko Asano
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
    Int J Hematol 91:426-35. 2010
    ..006). Multivariate analysis confirmed that the type 1 phenotype with CM expression was an independent prognostic factor. In both PTCL-N and ALK-negative ALCL, CM-positive type 1 disease had an extremely poor prognosis...
  11. ncbi Extranodal NK/T-cell lymphoma: diagnosis and treatment cues
    Ritsuro Suzuki
    Department of HSCT Data Management, Nagoya University, School of Medicine, Nagoya, Japan
    Hematol Oncol 26:66-72. 2008
    ..Therefore, new therapeutic approaches must be considered. Several new clinical trials are now being conducted in East Asia...
  12. ncbi Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma
    Keitaro Matsuo
    Aichi Cancer Center, Division of Epidemiology and Prevention, Nagoya, Japan
    Am J Hematol 77:351-7. 2004
    ..Lack of association with MTR polymorphism was also confirmed...
  13. ncbi Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma
    Yoshihiro Kameoka
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, Aichi, Japan
    Oncogene 23:9148-54. 2004
    ..These findings indicate that (1) loss of genomic material at 3q14.2 is responsible for exon losses of the FHIT gene, and (2) genomic loss of the FHIT gene is one of the causes of the generation of aberrant transcripts...
  14. ncbi Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified
    Naoko Asano
    Department of Pathology and Molecular Diagnostics, Division of Molecular Medicine, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
    Am J Surg Pathol 29:1284-93. 2005
    ..These findings suggest that nodal CM-positive PTCL-U show distinct clinicopathologic characteristics among the current category of PTCL-U...
  15. ncbi MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10
    Masao Nakagawa
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Blood 106:4210-6. 2005
    ..The nucleocytoplasmic shuttling of MALT1 and BCL10 complex may indicate that these molecules are involved not only in the nuclear factor kappaB (NF-kappaB) pathway but also in other biologic functions in lymphocytes...
  16. ncbi Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type
    Yoshinori Ito
    Department of Pediatrics, Nagoya University Graduate School of Medicine, Higashi ku, Nagoya, Japan
    Clin Cancer Res 18:4183-90. 2012
    ....
  17. ncbi Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement
    Ritsuro Suzuki
    Division of Molecular Medicine, Aichi Cancer Center, Nagoya, Japan
    Cancer 104:1022-31. 2005
    ..Although further investigations are needed to settle a marker for distinction, the presence of cutaneous involvement is a useful prognostic factor...
  18. ncbi Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study
    Takashi Ishida
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Blood 120:1734-41. 2012
    ..In conclusion, allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL...
  19. ncbi Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen
    Yoshihiro Inamoto
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
    Biol Blood Marrow Transplant 14:43-9. 2008
    ..No other secondary malignancies developed after long-term follow-up. Our findings suggest that TLI conditioning is feasible and effective for patients with AA...
  20. ncbi MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8
    Hiroyuki Tagawa
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Oncogene 23:2576-81. 2004
    ..This suggests that MASL1 is an important oncogene not only for solid tumors but also for hematologic malignancies...
  21. ncbi Lack of association between DNA base excision repair gene XRCC1 Gln399Arg polymorphism and risk of malignant lymphoma in Japan
    Keitaro Matsuo
    Aichi Cancer Center, Division of Epidemiology and Prevention, 1 1 Kanokoden Chikusa ku, Nagoya 464 8681, Japan
    Cancer Genet Cytogenet 149:77-80. 2004
    ..These data suggest that XRCC1 Gln399Arg polymorphism plays a limited role in lymphomagenesis. Further study on the interaction between the polymorphism and environmental exposure is required...
  22. ncbi Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission
    Satoshi NISHIWAKI
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
    Blood 116:4368-75. 2010
    ..After a close consideration of these factors, the outcome of allo-SCT for adult Ph(-) ALL in CR1 could be improved...
  23. ncbi Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review
    Yoshie Shimoyama
    Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan
    J Clin Exp Hematop 46:1-4. 2006
    ..Further investigations are necessary to clarify the interrelationship, including their overlapping morphological and biological features...
  24. ncbi Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan
    Minako Iida
    Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine, Nagoya, Japan
    Int J Hematol 93:523-31. 2011
    ..Thus, our findings suggest that MMF is safe and effective for the prevention and treatment of GVHD in patients who have received an allogeneic stem cell transplant...
  25. ncbi Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia
    Yoshiko Atsuta
    Department of HSCT Data Management Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Biol Blood Marrow Transplant 18:780-7. 2012
    ..28, 95% CI, 0.93-1.76; P = .125). HLA 0 to 2 antigen-mismatched UCBT is a reasonable second alternative donor/stem cell source with a survival outcome similar to that of single-HLA-DRB1-mismatched or other 7 of 8 UBMT...
  26. ncbi Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma
    Michinori Ogura
    Department of Hematology and Chemotherapy, Aichi Cancer Center Hospital, Nagoya, Japan
    Int J Hematol 77:503-11. 2003
    ..6%. These results indicated that CHASE is a safe and effective salvage regimen for malignant lymphoma, has sufficient mobilizing effect on peripheral blood stem cells, and warrants further phase II study...
  27. ncbi Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study
    Naoko Asano
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan
    J Clin Oncol 24:4626-33. 2006
    ..The aim of this study was to clarify the association between phenotypic expression and clinical outcome in CHL...
  28. ncbi Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type
    Ritsuro Suzuki
    Department of HSCT Data Management and Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Blood 118:6018-22. 2011
    ..9% and 94.4%, respectively (P = .0009). Plasma was a preferable sample for this purpose in NK/T-cell lymphoma, nasal type, and EBV-DNA level was a good indicator for response and overall survival...
  29. ncbi Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization
    Sivasundaram Karnan
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, Aichi, Japan
    Genes Chromosomes Cancer 39:77-81. 2004
    ..This indicates that CD5+ DLBCL constitutes a disease category distinct from that of CD5- DLBCL and other CD5+ malignancies...
  30. ncbi Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma
    Chunmei Li
    Department of Pathology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Mod Pathol 20:648-55. 2007
    ..Overexpression of the NPM-ALK fusion transcript may be associated with a poor prognosis of the patients with ALK(+) anaplastic large-cell lymphomas...
  31. ncbi NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm
    Ritsuro Suzuki
    Department of HSCT Data Management and Biostatistics, Nagoya University, Graduate School of Medicine, 1 1 20 Daiko Minami, Higashi ku, Nagoya, 461 0047, Japan
    Curr Oncol Rep 14:395-402. 2012
    ..Considering the myelotoxicity of SMILE, its use in the treatment of ANKL needs some modifications, but this treatment scheme is promising in improving the prognosis of NK-cell lymphomas...
  32. ncbi Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
    Yachiyo Kuwatsuka
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
    Blood 113:2096-103. 2009
    ..SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy...
  33. ncbi Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia
    Ritsuro Suzuki
    Department of HSCT Data Management and Biostatistics, Graduate School of Medicine, Nagoya University, 1 1 20 Daiko Minami, Higashi ku, Nagoya, 461 0047, Japan
    Int J Hematol 92:697-701. 2010
    ..ANKL needs another treatment strategy because of a systemic disease progression and extensive organ insufficiency. Optimal treatment scheme using such effective agents for these unfavorable NK-cell tumors should further be explored...
  34. ncbi Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System
    Yoshiko Atsuta
    Department of HSCT Data Management, Nagoya University, School of Medicine, Nagoya, Japan
    Int J Hematol 86:269-74. 2007
    ..While enhancing domestic registries, the program seeks to coordinate with other hematopoietic cell transplantation registries around the world to contribute to the development of registries throughout Asia...
  35. ncbi Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease
    Hiroshi Kimura
    Department of Virology Nagoya University Graduate School of Medicine, Nagoya, Japan
    Rev Med Virol 18:305-19. 2008
    ..The EBV real-time PCR assay system must be standardised for large-scale studies and international comparisons...
  36. ncbi Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study
    Yuichi Ishikawa
    Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Cancer Sci 101:2186-92. 2010
    ..A prospective intervention study is required to establish PK-based management in CML patients treated with imatinib...
  37. ncbi Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients
    Takashi Oyama
    Department of Hematology and Chemotherapy, Aichi Cancer Center, Nagoya, Japan
    Am J Surg Pathol 27:16-26. 2003
    ..Further investigations are needed to clarify the pathogenesis of this disease and to determine the optimal treatment strategy...
  38. ncbi Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group
    A Yoshimi
    Department of HSCT Data Management and Biostatistics, Nagoya University, School of Medicine, 1 1 20 Daiko Minami, Higashi ku, Nagoya, Japan
    Bone Marrow Transplant 45:1682-91. 2010
    ..This survey clearly shows the recent progress of HSCTs in Asia and also some differences in donor and stem cell selection and disease application among countries/regions...
  39. ncbi Pseudo-Gaucher cells in light chain plasma cell myeloma
    Yachiyo Kuwatsuka
    Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
    Am J Hematol 81:468-9. 2006
  40. ncbi Stability and subcellular localization of API2-MALT1 chimeric protein involved in t(11;18) (q21;q21) MALT lymphoma
    Koh Izumiyama
    Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan
    Oncogene 22:8085-92. 2003
    ..Our findings further suggest that the stabilized expression of API2-MALT1 products may continuously stimulate the NF-kappaB activating pathway, thus leading to MALT lymphomagenesis...
  41. ncbi Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor
    Maiko Asakura
    Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine, Higashi ku, Nagoya, Japan
    Int J Hematol 92:351-9. 2010
    ..Renal damage was only observed in 3% of patients. Foscarnet was concluded to be a safe and effective anti-CMV agent and to be a suitable alternative to ganciclovir...
  42. ncbi MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Masato Ito
    Second Department of Internal Medicine, Nagoya City University Medical School, Mizuho-ku, Nagoya 467-8601
    Jpn J Cancer Res 93:685-94. 2002
    ..The biological role and mechanism of action of MUM1 in B-CLL / SLL need to be clarified for the development of therapies for patients with the poor prognostic subtype...
  43. ncbi Centroblastic and centroblastic/centrocytic lymphoma associated with a prominent epithelioid granulomatous response: a clinicopathologic study of 50 cases
    Masaru Kojima
    Department of Pathology and Clinical Laboratories, Gunma Cancer Center Hospital, Ohta, Japan
    Mod Pathol 15:750-8. 2002
    ..The centroblastic and centroblastic/centrocytic lymphoma with an epithelioid cell response may be regarded as the morphologic variant of DLBCL preferentially arising in the aged population and reflecting the disease progression of FL...
  44. ncbi Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
    Tatsuya Suzuki
    Department of Infectious Diseases, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8560, Japan
    Blood 106:2854-61. 2005
    ..These results suggest that the NPM1 mutation is not necessarily an early event during leukemogenesis or that leukemia clones with NPM1 mutations are sensitive to chemotherapy...
  45. ncbi NK-cell neoplasms in Japan
    Kazuo Oshimi
    Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
    Hematology 10:237-45. 2005
    ..In nasal NK-cell lymphoma, Epstein-Barr virus in tumor cells was detected in all patients tested, suggesting its causative role...
  46. ncbi Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms
    Naoko Murashige
    Haematopoietic Stem Cell Transplantation Unit, the National Cancer Centre Hospital and Department of Cell Therapy and Transplantation Medicine, University of Tokyo, Japan
    Br J Haematol 130:561-7. 2005
    ..03), age (>or=40 years vs. <40 years; relative risk 2.85), and diagnoses (extranodal NK/T-cell lymphoma versus others; relative risk 3.94) significantly affected PFS. Allo-HSCT is a promising treatment for NK-cell neoplasms...
  47. ncbi De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients
    Motoko Yamaguchi
    Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2 174 Edobashi, Tsu, Mie 514 8507, Japan
    Haematologica 93:1195-202. 2008
    ..The aim of this retrospective study was to clarify the histopathological spectrum and obtain new information on the therapeutic implications of CD5(+) DLBCL...
  48. ncbi Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan
    Akiko M Saito
    Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Am J Hematol 82:873-80. 2007
    ..In older patients, RIST with fludarabine and busulfan was associated with acceptable toxicities and a satisfactory antileukemia effect, regardless of the early chimerism status...
  49. ncbi [Future perspectives of research and clinical studies for NK-cell malignancy in Asia]
    Ritsuro Suzuki
    Rinsho Ketsueki 49:559-63. 2008
  50. ncbi Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma
    Jun Ichi Tamaru
    Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
    Leuk Lymphoma 48:1127-38. 2007
    ..However, the patients with Hodgkin-like ALCL with CHL-immunophenotype (PAX-5/BSAP-positive and negative for Oct.2 and/or BOB.1) did not have a favorable outcome, with a 5-year OS rate of 58%...
  51. ncbi High-grade mature B-cell lymphoma with Burkitt-like morphology: results of a clinicopathological study of 72 Japanese patients
    Yuko Nomura
    Department of Pathology, School of Medicine, Kurume University, Asahimati 67, Kurume 830 0011, Japan
    Cancer Sci 99:246-52. 2008
    ..4; confidence interval 2.0-9.7; P = 0.0003). We concluded that aggressive short-term chemotherapy improves survival in BL/BLL, regardless of its genetic and immunophenotypic features...
  52. ncbi Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5
    Takuhei Murase
    Department of Internal Medicine, Nishio Municipal Hospital, 6 Kami awara, Kumamicho, Nishio, Aichi, and Department of Hematology, Mie University Graduate School of Medicine, Tsu, Japan
    Blood 109:478-85. 2007
    ..459), and thrombocytopenia less than 100x10(9)/L (P=.012, HR: 2.427) were independently unfavorable prognostic factors; CD5 positivity was not. Beyond immunophenotypic diversity, IVLBCL constitutes a unique group with aggressive behavior...
  53. ncbi Huge mass of cutaneous-type adult T-cell leukemia which responded to interferon gamma
    Taku Oba
    Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya
    Intern Med 46:147. 2007
  54. ncbi De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients
    Motoko Yamaguchi
    Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
    Blood 99:815-21. 2002
    ..Of particular interest is that CD5+ DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5- DLBCL (P =.0026). These findings suggest that CD5+ DLBCL may constitute a unique subgroup of DLBCL...
  55. ncbi [The unification of hematopoietic stem cell transplantation registry in Japan and establishment of the TRUMP system]
    Yoshiko Atsuta
    Department of HSCT Data Management, Nagoya University, School of Medicine
    Rinsho Ketsueki 48:1462-9. 2007
    ..While enhancing domestic registries, the program seeks to coordinate with other hematopoietic cell transplant registries around the world to contribute to the development of registries throughout Asia...
  56. ncbi [Molecular target therapy for malignant lymphoma]
    Ritsuro Suzuki
    Rinsho Ketsueki 49:18-29. 2008